Literature DB >> 22203669

Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1.

Bas Heinhuis1, Marije I Koenders, Wim B van den Berg, Mihai G Netea, Charles A Dinarello, Leo A B Joosten.   

Abstract

IL-32 can be expressed in several isoforms. The amino acid sequences of the major IL-32 isoforms were used to predict the secondary and tertiary protein structure by I-TASSER software. The secondary protein structure revealed coils and α-helixes, but no β sheets. Furthermore, IL-32 contains an RGD motif, which potentially activates procaspase-3 intracellular and or binds to integrins. Mutation of the RGD motif did not result in inhibition of the IL-32β- or IL-32γ-induced cytotoxicity mediated through caspase-3. Although IL-32α interacted with the extracellular part of αVβ3 and αVβ6 integrins, only the αVβ3 binding was inhibited by small RGD peptides. Additionally, IL-32β was able to bind to αVβ3 integrins, whereas this binding was not inhibited by small RGD peptides. In addition to the IL-32/integrin interactions, we observed that IL-32 is also able to interact with intracellular proteins that are involved in integrin and focal adhesion signaling. Modeling of IL-32 revealed a distinct α-helix protein resembling the focal adhesion targeting region of focal adhesion kinase (FAK). Inhibition of FAK resulted in modulation of the IL-32β- or IL-32γ-induced cytotoxicity. Interestingly, IL-32α binds to paxillin without the RGD motif being involved. Finally, FAK inhibited IL-32α/paxillin binding, whereas FAK also could interact with IL-32α, demonstrating that IL-32 is a member of the focal adhesion protein complex. This study demonstrates for the first time that IL-32 binds to the extracellular domain of integrins and to intracellular proteins like paxillin and FAK, suggesting a dual role for IL-32 in integrin signaling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22203669      PMCID: PMC3285345          DOI: 10.1074/jbc.M111.288290

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  74 in total

1.  Native IL-32 is released from intestinal epithelial cells via a non-classical secretory pathway as a membrane-associated protein.

Authors:  Haruki Hasegawa; Heather J Thomas; Ken Schooley; Teresa L Born
Journal:  Cytokine       Date:  2011-01       Impact factor: 3.861

2.  Regulated expression of focal adhesion kinase-related nonkinase, the autonomously expressed C-terminal domain of focal adhesion kinase.

Authors:  K Nolan; J Lacoste; J T Parsons
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

3.  Interleukin-32: a cytokine and inducer of TNFalpha.

Authors:  Soo-Hyun Kim; Sun-Young Han; Tania Azam; Do-Young Yoon; Charles A Dinarello
Journal:  Immunity       Date:  2005-01       Impact factor: 31.745

4.  The focal adhesion targeting (FAT) region of focal adhesion kinase is a four-helix bundle that binds paxillin.

Authors:  Ikuko Hayashi; Kristiina Vuori; Robert C Liddington
Journal:  Nat Struct Biol       Date:  2002-02

5.  Direct activation of caspases by RGD-peptides may increase drug sensitivity of tumour cells.

Authors:  Henk J. Broxterman; Klaas Hoekman
Journal:  Drug Resist Updat       Date:  1999-06       Impact factor: 18.500

6.  Negative feedback regulation of IL-32 production by iNOS activation in response to dsRNA or influenza virus infection.

Authors:  Wei Li; Fang Yang; Yan Liu; Rui Gong; Li Liu; Yong Feng; Pan Hu; Wei Sun; Qian Hao; Lei Kang; Jianguo Wu; Ying Zhu
Journal:  Eur J Immunol       Date:  2009-04       Impact factor: 5.532

7.  Proteinase 3-processed form of the recombinant IL-32 separate domain.

Authors:  Sunjong Kim; Siyoung Lee; Erk Her; Suyoung Bae; Jida Choi; Jaewoo Hong; Jun Jaekal; Doyoung Yoon; Tania Azam; Charles A Dinarello; Soohyun Kim
Journal:  BMB Rep       Date:  2008-11-30       Impact factor: 4.778

Review 8.  The ins and outs of leukocyte integrin signaling.

Authors:  Clare L Abram; Clifford A Lowell
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

9.  Endogenous IL-32 controls cytokine and HIV-1 production.

Authors:  Marcel F Nold; Claudia A Nold-Petry; Gregory B Pott; Jarod A Zepp; Milene T Saavedra; Soo-Hyun Kim; Charles A Dinarello
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.426

10.  Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases.

Authors:  Hirofumi Shoda; Keishi Fujio; Yumi Yamaguchi; Akiko Okamoto; Tetsuji Sawada; Yuta Kochi; Kazuhiko Yamamoto
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  29 in total

1.  Significant association between IL-32 gene polymorphisms and susceptibility to endometrial cancer in Chinese Han women.

Authors:  Xiuzhang Yu; Bin Zhou; Zhu Zhang; Qianqian Gao; Yanyun Wang; Yaping Song; Yan Pu; Yue Chen; Ruiqi Duan; Lin Zhang; Mingrong Xi
Journal:  Tumour Biol       Date:  2015-02-09

2.  Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.

Authors:  Kun-Yi Lai; Ya-Ching Chou; Jiun-Han Lin; Yi Liu; Kai-Min Lin; Shin-Lian Doong; Mei-Ru Chen; Te-Huei Yeh; Sue-Jane Lin; Ching-Hwa Tsai
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

3.  Interleukin-32β stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway.

Authors:  Jeong Su Park; Su Yun Choi; Jeong-Hyung Lee; Maria Lee; Eun Sook Nam; Ae Lee Jeong; Sunyi Lee; Sora Han; Myeong-Sok Lee; Jong-Seok Lim; Do Young Yoon; Yongil Kwon; Young Yang
Journal:  Cell Oncol (Dordr)       Date:  2013-10-10       Impact factor: 6.730

4.  IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression.

Authors:  Hanako Ohmatsu; Daniel Humme; Juana Gonzalez; Nicholas Gulati; Markus Möbs; Wolfram Sterry; James G Krueger
Journal:  Oncoimmunology       Date:  2016-05-05       Impact factor: 8.110

5.  IL-32 promotes angiogenesis.

Authors:  Claudia A Nold-Petry; Ina Rudloff; Yvonne Baumer; Menotti Ruvo; Daniela Marasco; Paolo Botti; Laszlo Farkas; Steven X Cho; Jarod A Zepp; Tania Azam; Hannah Dinkel; Brent E Palmer; William A Boisvert; Carlyne D Cool; Laima Taraseviciene-Stewart; Bas Heinhuis; Leo A B Joosten; Charles A Dinarello; Norbert F Voelkel; Marcel F Nold
Journal:  J Immunol       Date:  2013-12-11       Impact factor: 5.422

6.  IL-32α-induced inflammation constitutes a link between obesity and colon cancer.

Authors:  Victoria Catalán; Javier Gómez-Ambrosi; Amaia Rodríguez; Beatriz Ramírez; Victor A Ortega; José Luis Hernández-Lizoain; Jorge Baixauli; Sara Becerril; Fernando Rotellar; Víctor Valentí; Rafael Moncada; Camilo Silva; Javier Salvador; Gema Frühbeck
Journal:  Oncoimmunology       Date:  2017-05-16       Impact factor: 8.110

7.  The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.

Authors:  M López-Guerra; S Xargay-Torrent; L Rosich; A Montraveta; J Roldán; A Matas-Céspedes; N Villamor; M Aymerich; C López-Otín; P Pérez-Galán; G Roué; E Campo; D Colomer
Journal:  Leukemia       Date:  2014-04-30       Impact factor: 11.528

8.  IL-32γ promotes integrin αvβ6 expression through the activation of NF-κB in HSCs.

Authors:  Hongcan Liu; Xingfei Pan; Hong Cao; Xin Shu; Haixia Sun; Jianxi Lu; Jiayin Liang; Ka Zhang; Fengqin Zhu; Gang Li; Qi Zhang
Journal:  Exp Ther Med       Date:  2017-08-17       Impact factor: 2.447

Review 9.  IL-32θ: a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity.

Authors:  Muhammad Babar Khawar; Maryam Mukhtar; Muddasir Hassan Abbasi; Nadeem Sheikh
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 10.  Role of interleukin-32 in chronic rhinosinusitis.

Authors:  Anjeni Keswani; Robert C Kern; Robert P Schleimer; Atsushi Kato
Journal:  Curr Opin Allergy Clin Immunol       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.